With box warnings

Without box warnings

Branded

Generic

2 results

sarclisa
(isatuximab)
Sanofi-Aventis U.S. LLC
Usage: SARCLISA is indicated for the treatment of adult patients with multiple myeloma in combination with pomalidomide and dexamethasone after at least 2 prior therapies, or with carfilzomib and dexamethasone after 1 to 3 prior lines of therapy.
xpovio
(selinexor)
Karyopharm Therapeutics Inc.
Usage: XPOVIO is indicated for adults with multiple myeloma who have had prior therapy, in combination with bortezomib and dexamethasone, or dexamethasone alone for heavily pretreated patients. It is also approved for relapsed or refractory diffuse large B-cell lymphoma after at least two systemic therapies.

Medications for Relapsedrefractory Multiple Myeloma

sarclisa